Group 1 - The core viewpoint of the article highlights that Baiaosaitu-B (02315) has seen a significant increase of over 12%, reaching a new high of 35.86 HKD, driven by the announcement of its upcoming listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board [1] - The company announced that its ordinary shares will be listed on December 10, 2025, which is expected to enhance its market presence and investor interest [1] - According to Huafu Securities, the company's antibody licensing is beginning to yield results, indicating a strong growth potential and high barriers to entry in its business [1] Group 2 - The report emphasizes the solid foundation of the company's preclinical animal and pharmacological evaluations, suggesting a stable base for its antibody development business [1] - The potential of the new drug pipeline is highlighted, indicating that the company is entering a phase of performance realization [1] - The initial rating given by Huafu Securities is "Buy," reflecting confidence in the company's high growth prospects and market position [1]
港股异动 涨超12%创新高 即将登陆A股科创板 公司千鼠万抗开始兑现